Taletrectinib in ROS1 + Non–Small Cell Lung Cancer: TRUST
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index; 13 of the 37 sources its claims cite were checked for support.
Abstract
PURPOSE: Taletrectinib is an oral, potent, CNS-active, selective, next-generation ROS1 tyrosine kinase inhibitor (TKI). We report integrated efficacy and safety from registrational taletrectinib studies in ROS1 + non–small cell lung cancer. METHODS: TRUST-I and TRUST-II were phase II, single-arm, open-label, nonrandomized, multicenter trials. Efficacy outcomes were pooled from TRUST-I and TRUST-II pivotal cohorts. The safety population comprised all patients treated with once-daily oral taletrectinib 600 mg pooled across the taletrectinib clinical program. The primary end point was independent review committee–assessed confirmed objective response rate (cORR). Secondary outcomes included intracranial (IC)-ORR, progression-free survival (PFS), duration of response (DOR), and safety. RESULTS: As of June 7, 2024, the efficacy-evaluable population included 273 patients in TRUST-I and TRUST-II. Among TKI-naïve patients (n = 160), the cORR was 88.8% and the IC-cORR was 76.5%; in TKI-pretreated patients (n = 113), the cORR was 55.8% and the IC-cORR was 65.6%. In TKI-naïve patients, the median DOR and median PFS were 44.2 and 45.6 months, respectively. In TKI-pretreated patients, the median DOR and median PFS were 16.6 and 9.7 months. The cORR in patients with G2032R mutation was 61.5% (8 of 13). Among 352 patients treated with taletrectinib 600 mg once daily, the most frequent treatment-emergent adverse events (TEAEs) were GI events (88%) and elevated AST (72%) and ALT (68%); most were grade 1. Neurologic TEAEs were infrequent (dizziness, 21%; dysgeusia, 15%) and mostly grade 1. TEAEs leading to discontinuations (6.5%) were low. CONCLUSION: Taletrectinib showed a high response rate with durable responses, robust IC activity, prolonged PFS, favorable safety, and low rates of neurologic adverse events in TKI-naïve and pretreated patients.
Overview
CoChat Summary
TL;DR
Taletrectinib showed high, durable responses and robust intracranial activity in ROS1+ non–small cell lung cancer in an integrated analysis of TRUST-I and TRUST-II. It had favorable safety with low rates of neurologic adverse events.
Key findings
- In TKI-naïve patients (n = 160), the confirmed objective response rate (cORR) was 88.8%, intracranial cORR (IC-cORR) was 76.5%, median duration of response (DOR) was 44.2 months, and median progression-free survival (PFS) was 45.6 months.
- In TKI-pretreated patients (n = 113), cORR was 55.8%, IC-cORR was 65.6%, median DOR was 16.6 months, and median PFS was 9.7 months.
- Among patients with G2032R mutation, cORR was 61.5% (8 of 13).
- In the safety population (n = 352), common treatment-emergent adverse events were GI events (88%), elevated AST (72%), and elevated ALT (68%); neurologic events included dizziness (21%) and dysgeusia (15%), mostly grade 1; TEAEs leading to discontinuation were 6.5%.
Methods
- TRUST-I and TRUST-II were phase II, single-arm, open-label, nonrandomized, multicenter trials; efficacy was pooled from pivotal cohorts, and safety included all patients treated with once-daily oral taletrectinib 600 mg across the clinical program.
- The primary end point was independent review committee–assessed confirmed objective response rate; secondary outcomes included IC-ORR, PFS, DOR, and safety. As of June 7, 2024, the efficacy-evaluable population included 273 patients; safety population included 352 patients.
- Analyses used Clopper-Pearson 95% CIs, Kaplan-Meier estimates for PFS and DOR, and Greenwood/Brookmeyer-Crowley methods for corresponding CIs.
Limitations
- Stated: limited number of TKI-pretreated patients with baseline mutation status (71.7% unavailable) and follow-up biopsies because of difficulty obtaining rebiopsies at progression, limiting translational data on resistance mutations.
- Stated: cross-trial comparisons should be interpreted cautiously.
- Evident: the trials were single-arm, open-label, and nonrandomized without a concurrent control; the safety population was pooled across multiple studies, including a phase II trial in NTRK+ tumors and a phase I trial in Japan.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
8 Valid · 2 Not valid · 9 Not checked · 47 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In this integrated analysis, we show that the efficacy and safety results with taletrectinib observed in TRUST-I20 are generalizable to a global population of patients with ROS1+ NSCLC.”
§ Taletrectinib in ROS1+ Non–Small Cell Lung Cancer: TRUST > INTRODUCTION > CONTEXT
What the sources say
- Disputedcites [20] Li W Xiong A Yang N et al Efficacy and safety of taletrectinib in Chinese patients with ROS1+ non-small cell lung cancer: The phase II TRUST-I study J Clin Oncol 42 2660 2670 2024 38822758 PMC11272140 sourceExperimental — accuracy not yet measured
TRUST-I reports the opposite of generalizability to a global population: its DISCUSSION states the trial was 'geographically limited' and lists as a limitation 'that patients were from a single geographic region' (the study enrolled only 173 Chinese patients, per RESULTS > Patient Characteristics). The same DISCUSSION passage assigns the question of generality to a future trial, saying the ongoing pivotal, global phase II TRUST-II (NCT04919811) 'will further shed light on the generality of taletrectinib efficacy and safety profile across regions and ethnicities.' The Abstract PURPOSE and INTRODUCTION likewise frame the report as outcomes 'in China' / 'in Chinese patients with ROS1+ NSCLC,' so this source cannot support a claim that its results are established as generalizable globally. (LLM, conf=0.85)
Checked by a reasoning model — may be wrong.
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The recommended phase II dose (600 mg once daily) was established in two phase I trials conducted in the United States and Japan21,22 and confirmed during the safety lead-in of TRUST-I.20”
§ Taletrectinib in ROS1+ Non–Small Cell Lung Cancer: TRUST > INTRODUCTION > CONTEXT
What the sources say
- Not checked yetcites [21] Papadopoulos KP Borazanci E Shaw AT et al U.S. phase I first-in-human study of taletrectinib (DS-6051b/AB-106), a ROS1/TRK inhibitor, in patients with advanced solid tumors Clin Cancer Res 26 4785 4794 2020 32591465 source
- Partly supportedcites [22] Ou SHI Fujiwara Y Shaw AT et al Efficacy of taletrectinib (AB-106/DS-6051b) in ROS1+ NSCLC: An updated pooled analysis of U.S. and Japan phase 1 studies JTO Clin Res Rep 2 100108 2021 34589973 PMC8474193 sourceExperimental — accuracy not yet measured
The Materials and Methods section states 'The recommended phase 2 dose for Japanese patients was 600 mg once daily from the Japan phase 1 study,' and the Discussion refers to an ongoing large phase 2 trial of taletrectinib at 600 mg once daily — so the dose figure is supported. However, our copy attributes the 600 mg once daily RP2D specifically to the Japan (J102) study and to Japanese patients, while noting the maximum tolerated dose of 800 mg once daily was determined from the US phase 1 study; it does not state that the 600 mg RP2D was established jointly by both the U.S. and Japan trials as the citing sentence asserts. (LLM, conf=0.72)
- Supportedcites [20] Li W Xiong A Yang N et al Efficacy and safety of taletrectinib in Chinese patients with ROS1+ non-small cell lung cancer: The phase II TRUST-I study J Clin Oncol 42 2660 2670 2024 38822758 PMC11272140 source
The Methods (Study Design and Treatment) state that the recommended phase II dose established during phase I studies was 600 mg once daily and that its tolerability was confirmed during the TRUST-I safety lead-in, with stage II conducted at 600 mg once daily. This covers both parts attributed to this source: the RP2D value and its confirmation in TRUST-I's safety lead-in. The geographic detail of the phase I trials (US and Japan) is carried by the other citations, not this one. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“These data are comparable with responses seen with repotrectinib (ORR, 59%),17 suggesting that taletrectinib is a potential treatment option for patients with an ROS1 G2032R mutation.”
§ Taletrectinib in ROS1+ Non–Small Cell Lung Cancer: TRUST > DISCUSSION
What the sources say
- Supportedcites [17] Drilon A Camidge DR Lin JJ et al Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer N Engl J Med 390 118 131 2024 38197815 PMC11702311 source
The citation (ref. 17) is attached to the repotrectinib figure, and our copy states it directly: the Results (ACTIVITY IN ROS1+ NSCLC) report that of 17 TKI-pretreated patients with baseline ROS1 G2032R, ten had a confirmed response (59%; 95% CI, 33–82), echoed in the Abstract (RESULTS). The Discussion likewise frames this as confirmation of repotrectinib's activity against ROS1 solvent-front mutations. The trailing inference that taletrectinib is therefore a potential option is the citing authors' own conclusion; our copy mentions taletrectinib only in the Discussion as another next-generation ROS1 inhibitor in development (ref. 19), which does not contradict the attributed figure. (LLM, conf=0.88)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Overall, taletrectinib demonstrated a favorable tolerability and safety profile in patients with advanced ROS1+ NSCLC and other solid tumors treated at 600 mg once daily (N = 352).22”
§ Taletrectinib in ROS1+ Non–Small Cell Lung Cancer: TRUST > DISCUSSION
What the sources say
- Partly supportedcites [22] Ou SHI Fujiwara Y Shaw AT et al Efficacy of taletrectinib (AB-106/DS-6051b) in ROS1+ NSCLC: An updated pooled analysis of U.S. and Japan phase 1 studies JTO Clin Res Rep 2 100108 2021 34589973 PMC8474193 sourceExperimental — accuracy not yet measured
Our copy supports the qualitative tolerability claim: the Discussion states 'the side effects of taletrectinib are well tolerated' and the Abstract Conclusions report 'a manageable safety profile', with the Results (Adverse Events) giving ALT/AST elevation as the main grade >=3 events. However, the bounding qualifiers are not from this paper: the pooled analysis covers only 22 ROS1+ NSCLC patients (of 61 enrolled) given 400, 600, 800 and 1200 mg once daily plus 400 mg twice daily, with just 6 patients at 600 mg once daily (Table 1), and it reports no N = 352 safety population and no 'other solid tumors' cohort beyond a single thyroid-cancer patient credited to the US phase 1 trial (Papadopoulos et al., ref. 6). The dose- and N-specific parts of the claim are therefore unsupported by this source. (LLM, conf=0.78)
boostedn = 352- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“As previously reported, the selectivity of taletrectinib for ROS1 over TrKB may explain the lower rates and narrower spectrum of neurologic side effects versus other ROS1 TKIs.20”
§ Taletrectinib in ROS1+ Non–Small Cell Lung Cancer: TRUST > DISCUSSION
What the sources say
- Partly supportedcites [20] Li W Xiong A Yang N et al Efficacy and safety of taletrectinib in Chinese patients with ROS1+ non-small cell lung cancer: The phase II TRUST-I study J Clin Oncol 42 2660 2670 2024 38822758 PMC11272140 sourceExperimental — accuracy not yet measured
The DISCUSSION of our copy states almost exactly the attributed point, with the same hedge: 'The selectivity profile of taletrectinib for ROS1 over TRKB may explain the relatively lower rates of AEs such as dizziness (23.1%), dysgeusia (10.4%), and hypesthesia (7.5%) versus other ROS1 TKIs' — so the 'lower rates' component and the ROS1-over-TRKB selectivity explanation are supported (backed by the INTRODUCTION's in vitro IC50 data, 0.07 nM ROS1 v 1.47 nM TRKB). However, our copy nowhere claims a 'narrower spectrum' of neurologic side effects; it only reports lower rates of named events, mostly grade 1, and explicitly notes that rates were comparable with crizotinib (dizziness 16.0%, dysgeusia 16.0%), so the spectrum breadth is the citing authors' addition. The citing sentence also drops the source's accompanying caveat that 'the relationship between these observed neurologic AEs and potential TRKC inhibition cannot be excluded.' (LLM, conf=0.70)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
33 more claims
Create a free account to see all 66 claims and to verify the 24 references still open.
- Probably not a substantial claim. 14
- It may state two separate claims as one. 17
- The quote only partly states this claim. 1
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.11.025 · Cited by 2,317
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Bergethon, K., Shaw, A. T., Ignatius Ou, S.-H., Katayama, R., Lovly, C. M., McDonald, N. T., Massion, P. P., Siwak-Tapp, C., Gonzalez, A., Fang, R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6345 · Cited by 1,555
Shaw, A. T., Riely, G. J., Bang, Y.-J., Kim, D.-W., Camidge, D. R., Solomon, B. J., Varella-Garcia, M., Iafrate, A. J., Shapiro, G. I., Usari, T., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz131 · Cited by 576
Drilon, A., Ou, S.-H. I., Cho, B. C., Kim, D.-W., Lee, J., Lin, J. J., Zhu, V. W., Ahn, M.-J., Camidge, D. R., Nguyen, J., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0484 · Cited by 504 · cited 1×
“16,17 While active against G2032R and brain metastases, a high incidence and wide spectrum of neurologic adverse events (AEs) were observed in most patients receiving repotrectinib.”
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer
Pietrantonio, F., Di Nicolantonio, F., Schrock, A. B., Lee, J., Tejpar, S., Sartore-Bianchi, A., Hechtman, J. F., Christiansen, J., Novara, L., Tebbutt, N., et al. (2017) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx089 · Cited by 317
Gainor, J. F., Tseng, D., Yoda, S., Dagogo-Jack, I., Friboulet, L., Lin, J. J., Hubbeling, H. G., Dardaei, L., Farago, A. F., Schultz, K. R., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00063 · Cited by 264
Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer
Drilon, A., Camidge, D. R., Lin, J. J., Kim, S.-W., Solomon, B. J., Dziadziuszko, R., Besse, B., Goto, K., de Langen, A. J., Wolf, J., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2302299 · Cited by 240 · cited 3×
“…in Japan and the United States, 21 similar responserates andsafety pro fi les were also observed in TKI-na¨ ı ve patients from a global or Asian population of patients receiving crizotinib, 11,26 entrectinib, 15,27 and repotrectinib 17,28 and in TKI-pretreated patients receiving repotrectinib.”
Self-citationPatil, T., Smith, D. E., Bunn, P. A., Aisner, D. L., Le, A. T., Hancock, M., Purcell, W. T., Bowles, D. W., Camidge, D. R., & Doebele, R. C. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.07.001 · Cited by 205
Research works printed but not linked: 1
- US Food and Drug Administration: Guidance for Industry—Drug-Induced Liver Injury: Premarketing Clinical Evaluation. Silver Spring, MD, U.S. Department of Health and Human Services, 2009
Cited by
Lung Cancer in Nonsmoking Individuals: A Review
Murphy, C., Pandya, T., Swanton, C., & Solomon, B. (2025) · JAMA · doi:10.1001/jama.2025.17695 · Cited by 67
Properties of FDA-approved small molecule protein kinase inhibitors: A 2026 update
Roskoski, R. J. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108107 · Cited by 61
Puri, S., Leighl, N. B., Ismaila, N., Rous, F. A., Ahluwalia, A., Alluri, K. C., Azar, I. H., Campbell, T., Durm, G. A., Feldman, J., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-02822 · Cited by 46
Self-citationMishra, S., Chetna, J., Cardoza, S., Potuganti, G. R., & Velma, G. R. (2026) · RSC Advances · doi:10.1039/d6ra01711h · Cited by 24
Nitrogen-containing FDA-approved drugs in 2025: synthesis, significance and therapeutic applications
Chetna, J., Mishra, S., Potuganti, G. R., Cardoza, S., & Velma, G. R. (2026) · RSC Advances · doi:10.1039/d6ra00737f · Cited by 18
Metadata
- Authors
- Pérol, M., Li, W., Pennell, N. A., Liu, G., Ohe, Y., De Braud, F., Nagasaka, M., Felip, E., Xiong, A., Zhang, Y., Fan, H., Wang, X., Li, S., Lai, R. K., Ran, F., Zhang, X., Chen, W., Bazhenova, L., & Zhou, C.
- Affiliations
- Department of Medical Oncology, Léon Bérard Cancer Center, Lyon, France
- Tongji University (CN)
- Cleveland Clinic (US)
- University of Toronto (CA)
- National Cancer Center Hospital (JP)
- University of Milan, Milan, Italy
- University of California, Irvine (US)
- Vall d'Hebron Hospital Universitari (ES)
- Central South University (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
- Guangdong Pharmaceutical University (CN)
- Nuvation Bio, New York, NY
- Moores Cancer Center (US)
- Corresponding author
- Zhou, Caicun
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2025-06
- Volume
- 43
- Issue
- 16
- Pages
- 1920-1929
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- PMC
- PMC12118623
- OpenAlex
- W4409129984
- Cited by
- 63
- References
- 25
- Citations by year
- 2026: 43 · 2025: 20
- FWCI
- 41.42
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Journal of Clinical Oncology (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- taletrectinib, ROS1-positive non-small cell lung cancer, tyrosine kinase inhibitors, objective response rate, intracranial response, progression-free survival, duration of response, treatment-emergent adverse events, neurological adverse events
- MeSH terms
- Progression-Free Survival, Adult, Aged, Aged, 80 and over, Anilides, Carcinoma, Non-Small-Cell Lung, Female, Humans, Imidazoles, Lung Neoplasms, Male, Middle Aged, Protein-Tyrosine Kinases, Proto-Oncogene Proteins, Pyrazoles, Pyridazines, Quinolines, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Taletrectinib in ROS1 + Non–Small Cell Lung Cancer: TRUST. https://app.cochat.ai/papers/10.1200/jco-25-00275
- The paper
- Pérol, M., Li, W., Pennell, N. A., Liu, G., Ohe, Y., De Braud, F., Nagasaka, M., Felip, E., Xiong, A., Zhang, Y., Fan, H., Wang, X., Li, S., Lai, R. K., Ran, F., Zhang, X., Chen, W., Bazhenova, L., & Zhou, C. (2025). Taletrectinib in ROS1 + Non–Small Cell Lung Cancer: TRUST. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-00275
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.